Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Spencer

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Annals of Internal Medicine|June 27, 2022
Life Expectancy for White, Black, and Hispanic Race/Ethnicity in U.S. States: Trends and Disparities, 1990 to 2019Catherine O Johnson, Alexandra S Boon-Dooley, Nicole K DeCleene, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinomaEileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
Oncoimmunology|July 7, 2017
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot studyYong Qin, Mariana Petaccia de Macedo, Alexandre Reuben, et al.
Cancer Discovery|April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and ImmunityIsabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
The Journal of Clinical Investigation|February 17, 2026
Pathobiont-triggered induction of goblet cell response drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Monica E Brown, Erin P Smith, et al.
Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Pathobiont-triggered induction of epithelial IDO1 drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Jiawei Wang, Erin P Smith, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Annals of Internal Medicine|June 27, 2022
Life Expectancy for White, Black, and Hispanic Race/Ethnicity in U.S. States: Trends and Disparities, 1990 to 2019Catherine O Johnson, Alexandra S Boon-Dooley, Nicole K DeCleene, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinomaEileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
Oncoimmunology|July 7, 2017
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot studyYong Qin, Mariana Petaccia de Macedo, Alexandre Reuben, et al.
Cancer Discovery|April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and ImmunityIsabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
The Journal of Clinical Investigation|February 17, 2026
Pathobiont-triggered induction of goblet cell response drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Monica E Brown, Erin P Smith, et al.
Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Pathobiont-triggered induction of epithelial IDO1 drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Jiawei Wang, Erin P Smith, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Pageof 21